BACKGROUND: Computed tomography (CT) remains the standard neuroimaging screening exam for neurocysticercosis, and residual brain calcifications are the commonest finding. Magnetic resonance imaging (MRI) is more sensitive than CT but is rarely available in endemic regions. Enzyme-linked immunoelectrotransfer blot (EITB) assay uses antibody detection for diagnosis confirmation; by contrast, enzyme-linked immunosorbent assay (ELISA) antigen detection (Ag-ELISA) detects circulating parasite antigen. This study evaluated whether these assays predict undetected viable cysts in patients with only calcified lesions on brain CT. METHODS: Serum samples from 39 patients with calcified neurocysticercosis and no viable parasites on CT were processed by Ag-ELISA and EITB. MRI was performed for each patient within 2 months of serologic testing. Conservatively high ELISA and EITB cutoffs were used to predict the finding of viable brain cysts on MRI. RESULTS: Using receiver operating characteristic-optimized cutoffs, 7 patients were Ag-ELISA positive, and 8 had strong antibody reactions on EITB. MRI showed viable brain cysts in 7 (18.0%) patients. Patients with positive Ag-ELISA were more likely to have viable cysts than Ag-ELISA negatives (6/7 vs 1/32; odds ratio, 186 [95% confidence interval, 1-34 470.0], P < .001; sensitivity 85.7%, specificity 96.9%, positive likelihood ratio of 27 to detect viable cysts). Similar but weaker associations were also found between a strong antibody reaction on EITB and undetected viable brain cysts. CONCLUSIONS: Antigen detection, and in a lesser degree strong antibody reactions, can predict viable neurocysticercosis. Serological diagnostic methods could identify viable lesions missed by CT in patients with apparently only calcified cysticercosis and could be considered for diagnosis workup and further therapy.
BACKGROUND: Computed tomography (CT) remains the standard neuroimaging screening exam for neurocysticercosis, and residual brain calcifications are the commonest finding. Magnetic resonance imaging (MRI) is more sensitive than CT but is rarely available in endemic regions. Enzyme-linked immunoelectrotransfer blot (EITB) assay uses antibody detection for diagnosis confirmation; by contrast, enzyme-linked immunosorbent assay (ELISA) antigen detection (Ag-ELISA) detects circulating parasite antigen. This study evaluated whether these assays predict undetected viable cysts in patients with only calcified lesions on brain CT. METHODS: Serum samples from 39 patients with calcified neurocysticercosis and no viable parasites on CT were processed by Ag-ELISA and EITB. MRI was performed for each patient within 2 months of serologic testing. Conservatively high ELISA and EITB cutoffs were used to predict the finding of viable brain cysts on MRI. RESULTS: Using receiver operating characteristic-optimized cutoffs, 7 patients were Ag-ELISA positive, and 8 had strong antibody reactions on EITB. MRI showed viable brain cysts in 7 (18.0%) patients. Patients with positive Ag-ELISA were more likely to have viable cysts than Ag-ELISA negatives (6/7 vs 1/32; odds ratio, 186 [95% confidence interval, 1-34 470.0], P < .001; sensitivity 85.7%, specificity 96.9%, positive likelihood ratio of 27 to detect viable cysts). Similar but weaker associations were also found between a strong antibody reaction on EITB and undetected viable brain cysts. CONCLUSIONS: Antigen detection, and in a lesser degree strong antibody reactions, can predict viable neurocysticercosis. Serological diagnostic methods could identify viable lesions missed by CT in patients with apparently only calcified cysticercosis and could be considered for diagnosis workup and further therapy.
Authors: Raúl J Bobes; Marisela Hernández; Carlos Márquez; Gladis Fragoso; Esperanza García; R Michael E Parkhouse; Leslie J S Harrison; Edda Sciutto; Agnès Fleury Journal: Trop Med Int Health Date: 2006-06 Impact factor: 2.622
Authors: M E Cruz; P M Schantz; I Cruz; P Espinosa; P M Preux; A Cruz; W Benitez; V C Tsang; J Fermoso; M Dumas Journal: Int J Epidemiol Date: 1999-08 Impact factor: 7.196
Authors: Silvia Rodriguez; Pierre Dorny; Victor C W Tsang; E Javier Pretell; Jef Brandt; Andres G Lescano; Armando E Gonzalez; Robert H Gilman; Hector H Garcia Journal: J Infect Dis Date: 2009-05-01 Impact factor: 5.226
Authors: H H Garcia; L J Harrison; R M Parkhouse; T Montenegro; S M Martinez; V C Tsang; R H Gilman Journal: Trans R Soc Trop Med Hyg Date: 1998 Jul-Aug Impact factor: 2.184
Authors: H H Garcia; G Herrera; R H Gilman; V C Tsang; J B Pilcher; J F Diaz; E J Candy; E Miranda; J Naranjo Journal: Am J Trop Med Hyg Date: 1994-02 Impact factor: 2.345
Authors: Gianfranco Arroyo; Javier A Bustos; Andres G Lescano; Isidro Gonzales; Herbert Saavedra; E Javier Pretell; Yesenia Castillo; Erika Perez; Pierre Dorny; Robert H Gilman; Seth E O'Neal; Armando E Gonzalez; Hector H Garcia Journal: J Clin Microbiol Date: 2021-12-01 Impact factor: 11.677
Authors: Karen A Alroy; Gianfranco Arroyo; Robert H Gilman; Eloy Gonzales-Gustavson; Linda Gallegos; Cesar M Gavidia; Manuela Verastegui; Silvia Rodriguez; Teresa Lopez; Luis A Gomez-Puerta; Joseph Alroy; Hector H Garcia; Armando E Gonzalez Journal: Am J Trop Med Hyg Date: 2018-06-07 Impact factor: 2.345
Authors: Gianfranco Arroyo; Silvia Rodriguez; Andres G Lescano; Karen A Alroy; Javier A Bustos; Saul Santivañez; Isidro Gonzales; Herbert Saavedra; E Javier Pretell; Armando E Gonzalez; Robert H Gilman; Victor C W Tsang; Hector H Garcia Journal: Clin Infect Dis Date: 2018-01-06 Impact factor: 9.079
Authors: Kabemba E Mwape; Joachim Blocher; Jasmin Wiefek; Kathie Schmidt; Pierre Dorny; Nicolas Praet; Clarance Chiluba; Holger Schmidt; Isaac K Phiri; Andrea S Winkler; Sarah Gabriël Journal: PLoS Negl Trop Dis Date: 2015-08-18
Authors: Paul T Cantey; Christina M Coyle; Frank J Sorvillo; Patricia P Wilkins; Michelle C Starr; Theodore E Nash Journal: Am J Trop Med Hyg Date: 2014-05 Impact factor: 2.345